INTRODUCTION
Thymidine kinase (TK, EC 2.7.1.21), a ubiquitous enzyme of the salvage pathway of nucleoside metabolism, catalyses the phosphorylation of thymidine (TdR) to thymidylate (TMP) using ATP as the phosphate donor.
In contrast with the cellular TK, the Herpes simplex virus type 1 (HSV-1) TK possesses not only thymidine kinase activity but also deoxycytidine kinase activity, which phosphorylates deoxycytidine to dCMP (Jamieson et al., 1974; Thouless and Wildy, 1975) , and thymidylate kinase (TMPK) activity, which phosphorylates TMP to TDP (Cheng, 1976; Cheng et al., 1979) . Furthermore, the viral TK, because of its low substrate specificity, can also phosphorylate to mono-and/or di-phosphate forms a wide variety of pyrimidine and purine nucleoside analogues (Fyfe et al., 1978; Fyfe, 1982; Cheng and Prusoff, 1986; De Clercq, 1988) , which represent most of the anti-herpetic drugs clinically used or under scientific investigation (De Clercq, 1988; Mertz, 1990) . These modified nucleoside analogues exert their anti-herpetic activity when converted ultimately into the active triphosphate form by cellular enzymes. In this form they preferentially inhibit the viral DNA polymerase or are incorporated into the viral DNA interfering with the replication or transcription of the viral genome (Wright and Brown, 1990; Balzarini et al., 1990) . It is known that the phosphorylation of these analogues from diphosphates to triphosphates is carried out by non-specific cellular nucleoside diphosphate kinases and is not a limiting step in the activation of the drugs. In contrast, the phosphorylation of the nucleosides to monophosphates by the HSV-1 TK and of the mono-to di-phosphates by the HSV-1 TK; (iii) both viral TK and TMPK activities are inhibited, in a competitive way and with identical Ki values, by novel, nonsubstrate inhibitors of HSV-1 TK, N2-phenylguanines; (iv) LTdR is phosphorylated to L-TMP by the viral TK, but L-TMP is not phosphorylated to L-TDP by the viral TMPK activity; and (v) L-TMP inhibits competitively and with identical potencies the phosphorylation of TdR and TMP catalysed respectively by the HSV-1 TK and TMPK activities. In conclusion, our data demonstrate that both TK and TMPK activities encoded by HSV-1 share a common active site which is very tolerant in accepting modified nucleosides, but cannot readily accommodate modified nucleoside monophosphates.
TMPK are crucial steps for their activation, since the cellular nucleoside kinases and monophosphate kinases are generally more selective than the viral enzyme in the recognition of the substrate (Cheng and Prusoff, 1986; De Clercq and Walker, 1988; Dorsky and Crumpacker, 1987; Descamps and De Clercq, 1981) . Thus, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), which is phosphorylated to BVdUMP by both HSV-l and HSV-2 TKs, is exceptionally active against HSV-1 proliferation, but displays a modest activity against HSV-2. This is ascribed to the fact that HSV-2 TK, in contrast with HSV-I TK, lacks a TMPK activity and is thus unable to phosphorylate BVdUMP to BVdUDP. However, not all the nucleoside analogues which are phosphorylated by the HSV-l TK are by definition substrates for the HSV-1 TMPK. In fact, acyclovir (ACV), which is phosphorylated by the HSV-1 TK to ACV monophosphate, is not further transformed to ACV diphosphate by HSV-1 TMPK but by cellular kinases (Miller and Miller, 1980) . These data suggest that TMPK associated with the HSV-l TK activity is more stringent than the latter in the acceptance of the substrate, and this raises the question as to whether one or more sites are involved in the phosphorylation of both TdR and TMP catalysed by the HSV-1 TK and TMPK activities.
Since HSV-l-encoded TK and TMPK activities could not be separated by affinity column chromatography, by glycerolgradient centrifugation or by isoelectric focusing (Cheng and Prusoff, 1978) , both activities may reside on the same polypeptide. Kinetic studies by Cheng and co-workers (1979) inhibitors (N2-phenylguanines) and substrate inhibitors (Lthymidine) of HSV-1 TK, described by our group (Focher et al., 1988; Spadari and Wright, 1989; Hildebrand et al., 1990; Spadari et al., 1992) for the active site of the HSV-1 TMPK. N2-phenylguanines competitively inhibit, in the micromolar range, the phosphorylation of [3H]thymidine by HSV-1 TK (Focher et al., 1988; Spadari and Wright, 1989; Hildebrand et al., 1990) and also inhibit the reactivation of HSV-1 from infected neuronal ganglia (Leib et al., 1990) . On the other hand, L-thymidine not only competitively inhibits the phosphorylation of [3H]thymidine by HSV-1 TK, but it is phosphorylated to its monophosphate form with a Km of 2 ,IM. Furthermore, at 90 #M, L-thymidine reduces by more than two orders of magnitude the HSV-1 multiplication.
The studies here described allow to conclude that both TK and TMPK activities encoded by HSV-1 share a common active site.
MATERIALS AND METHODS Chemicals and enzyme
TdR: 6 Ci/mmol) was from Moravek Biochemicals.
[14C]TMP (40 mCi/mmol) was from ICN Flow. Polyethyleneimine (PEI)cellulose F plastic sheets (layer thickness 0.1 mm) for t.l.c. were from Merck. All other chemicals and reagents were purchased from local suppliers. TK was purified HeLa TK-infected cells as described by Focher et al. (1988) . Membranes and mitochondria still present in the cytoplasm after earlier centrifugations were eliminated by ultracentrifugation at 100000 g for 30 min.
Inhibitors
L-Nucleosides were synthesized as described in Spadari et al. (1992) . N2-Phenylguanines were synthesized as described by Focher et al. (1988) and Hildebrand et al. (1990) .
Thymidine kinase assay TK was assayed as follows: 0.02 unit of enzyme was incubated at 37°C for 30 min in 25 ,t1 of a mixture containing 30 mM potassium Hepes, pH 7.5, 6 mM MgCl2, 6 mM ATP, 0.5 mM dithiothreitol (DTT) and 3.3 ,uM [3H]TdR (1500 c.p.m./pmol) or 10 ,uM L-[3H]TdR (660 c.p.m./pmol). The reaction was terminated by spotting 20 ,ul of the incubation mixture on a 25 mmdiameter DEAE-cellulose paper disc (DE-81 paper; Whatman). The disc was washed twice in an excess of 1 mM ammonium formate, pH 3.6, in order to remove unconverted nucleoside and then once in distilled water and finally in ethanol. Radioactive TMP or L-TMP was estimated by scintillation counting in 1 ml of Betamax (ICN-Biomedicals). 
RESULTS
TdR is a competitive inhibitor of TMP phosphorylation catalysed by the HSV-1 TMPK Previous kinetic studies showed that TMP is a product inhibitor of TdR phosphorylation catalysed by the HSV TK, with a K, identical with its Km as substrate for the viral TMPK (Cheng et al., 1979) . In the reciprocal experiment we have found that TdR is also a competitive inhibitor of the TMP phosphorylation catalysed by HSV-1 TMPK (Figure 1) (Figure 2) , with a Ki calculated from a Dixon plot of 1.0 + 0.1 ,uM, identical with the Km value of L-TdR for the HSV-1 TK, which is 1.01 + 0.05 juM. We also found that TMP inhibited L-TdR phosphorylation catalysed by the HSV-l TK ( Figure 3) To verify this assumption, we challenged the TMPK activity encoded by HSV-I with a group of N2-phenylguanines, synthesized and characterized in our laboratory (Focher et al., 1988; Spadari and Wright, 1989; Hildebrand et al., 1990) , which specifically inhibit the viral TK. These compounds are not phosphorylated by the viral TK and, once bound to the active site, they block the enzyme by presumably occupying the TdRbinding site.
These non-substrate inhibitors of HSV-l TK were found to be competitive inhibitors also of the viral TMPK, as shown in Table   1 Only L-TMP accumulated in the course of the reaction with LTdR, whereas no detectable amounts of L-TDP were formed during the 60 min of incubation time (Figure 4) , even using higher concentrations of enzyme (results not shown). In a control reaction with TdR, both TMP and TDP were formed at appreciable levels (Figure 4) 
DISCUSSION
We have co-purified, through ion-exchange and affinity column chromatography, the viral TK and TMPK activities from HSV-I infected HeLa TK-cells, as previously described (Focher et al., 1988) , and we have investigated whether one or more active sites were involved in the phosphorylation of TdR and TMP by a double approach. First, we have studied the kinetics of interaction of nucleosides, which are substrates for the HSV-l TK, with the HSV-l TMPK activity, both of the natural D configuration and of the unnatural L configuration. Secondly, we have tested as inhibitors of the HSV-l TMPK, a series of highly specific nonsubstrate competitive inhibitors of the HSV-l TK, the N2-phenylguanines, developed and exstensively characterized by us (Focher et al., 1988; Spadari and Wright, 1989; .
All data reported here can be explained in a satisfactory way only assuming that a common active site is involved in the phosphorylation of both TdR and TMP. When we studied the interaction of L-TMP with the HSV-1 TMPK activity, we obtained data showing that L-TdR, after being converted into L-TMP by the viral TK, is not further phosphorylated to L-TDP by the associated TMPK activity. According to the hypothesis that a single active site is shared by both the TK and TMPK activities, the dissociation constants of L-TMP derived from Dixon plots are identical (680 and 700 ,uM respectively). The low affinity of L-TMP for the active site of the viral TK and TMPK activities can explain why we were not able to detect L-TDP in our assays in the presence of 10 ,uM L-TdR as substrate. It has been shown (Cheng et al., 1979) that the first phosphorylated product of the reaction, TMP, leaves the active site and that it has to reassociate before being further phosphorylated to TDP. The direct channelling of TdR to TDP does not appear to be a significant route. It is possible that, once phosphorylated, the furanosyl ring with the unnatural L configuration cannot be readily accommodated into the active site of the enzyme due to the steric impedence of the 5'-phospho group. This could explain both the low affinity of L-TMP for the enzyme and the fact that L-TdR, which is readily phosphorylated by the HSV-1 TK, has only a relatively low potency against HSV-1 replication in infected cells (Spadari et al., 1992) . It is possible that a similar mechanism could be responsible for the lack of phosphorylation of ACV monophosphate by the HSV-1 TMPK activity.
In conclusion, our results suggest that the active site shared by the HSV-1 TK and TMPK activities can readily accommodate nucleoside analogues with several modifications both in the base and in the sugar ring, but it is not so tolerant in the acceptance of the same analogues once they are phosphorylated in the 5'-position of the sugar ring. These observations could be relevant in designing new antiviral nucleosides.
